# **Duplicate Review**

# Why Review Duplicates?

AutoLit provides automatic de-duplication, meaning that whenever you complete multiple searches (or import multiple RIS/nBIB files), an algorithm compares the DOI, PMID, PMCID, title, and abstract, and keeps only one version of any studies that match across these fields with a high enough certainty. However, if you want to ensure that all de-duplicated records are in fact duplicates, this page enables manual review of all de-duplication decisions.

## Navigate to the Duplicate Review Page

Under Literature Search, select "Duplicate Review" ( red box ).

## **Downloading Duplicate Queue**

Prior to clearing any records from the duplicate records, you may want to download a spreadsheet of duplicates found. It is important to do this BEFORE making any individual decisions or clearing the queue if you want a full record of all duplicates!

The spreadsheet will only download records that are still in the queue.

To do this, click "Download Queue"

Download Queue 🕢			D	upl	licate Queue			Clear Queue
Title ↑↓	Author ↑↓	Year ↑↓	Time of Search	$\downarrow$	Search ↑↓	Duplicate Type	¢↓	Reason ↑↓
A Phase 3 Study of Efficacy and Safety of Remibruti		2021	Jun 12, 202	3	ClinicalTrials.gov: AREA[OverallStatus] EXPAND[Ter	Duplicate		Detected similarity on title (Jaro-W
A Phase III Study of Safety and Efficacy of Ligelizum		2018	Jun 12, 202	2	ClinicalTrials.gov: AREA[OverallStatus] EXPAND[Ter Duplicates	Duplicate		Detected similarity on title (Jaro-W



### **Review Duplicate Records**

After downloading the spreadsheet of duplicates, you are free to explore the list of all records that were removed from the nest as duplicates of existing records. While the basic information about the record is shown in the table, to review an individual record, click on the row to open the Duplicate Review modal.

Download Queue 🕢	Duplicate Queue Clear Queue							
Title ∩J	Author ↑↓	Year ↑↓	Time of Search	$\downarrow$	Search ↑↓	Duplicate Type	î↓	Reason ↑↓
A Phase 3 Study of Efficacy and Safety of Remibruti		2021	Jun 12, 2	023	ClinicalTrials.gov: AREA[OverallStatus] EXPAND[Ter	Duplicate		Detected similarity on title (Jaro-W
A Phase III Study of Safety and Efficacy of Ligelizum		2018	Jun 12, 2	023 2	ClinicalTrials.gov: AREA[OverallStatus] EXPAND[Ter Duplicates	Duplicate		Detected similarity on title (Jaro-W

Alternatively, you can "Clear Queue" and make a bulk decision for all records in the queue. You can decide to keep all the duplicates as separate records, or drop all duplicates, which automatically removes them from your nest.

### **Manually Edit De-duplication**

Once you have selected a record, you can see and edit the bibliographic information of both the record that was kept in the nest and the record that was removed as a duplicate. Any differences in bibliographic information are presented in red text to highlight potential differences. From this page, you can do several things:

### **1. Override De-duplication**

If the de-duplication was in error (and both records should be added to the nest as separate studies), select "Keep Both Records Separately" to over to insert each one into your nest.

### 2. Confirm De-duplication

If, upon review, a de-duplication decision that you are reviewing is correct, you can click "Keep only this record," "cancel," or click out of the modal to confirm the de-duplication decision.

### 3. Edit the Record

If the bibliographic information for the record that was kept is incorrect, you can edit it from this portal. To edit, click on any field and type in the correct bibliographic information.

#### **Override Auto-Deduplication**

Duplicate detection: Detected similarity	on title (Jaro-Winkler similarity of 0.981 exceeded threshold	0.95)					
his record is already in your nest:		This record was marked as a duplica	ate:				
Title: A Phase III Study of Efficacy and Saf	ety of Ligelizumab in the Treatment of CSU in	Title: A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in					
Adolescents and Adults Inadequately	Controlled With H1-antinistamines.	Adolescents and Adults Inadequate	ely Controlled with H1-antinistamines				
Abstract: Brief Summary: The purpose of this s ligelizumab in adolescent and adult s standard of care treatment by demon placebo. The study population consis years who were diagnosed with CSU	study was to establish efficacy and safety of ubjects with CSU who remained symptomatic despite istrating better efficacy over omalizumab and over sted of 1,079 male and female subjects aged $\geq$ 12 and who remained symptomatic despite the use of $_{a}$	Abstract: Brief Summary: The purpose of this ligelizumab in adolescent and adult who remain symptomatic despite st efficacy over omalizumab and over and female subjects aged ≥ 12 year	s study was to establish safety and efficacy of subjects with Chronic Spontaneous Urticaria (CSU) andard of care treatment by demonstrating better placebo. The study population consisted of 1,072 male rs who were diagnosed with CSU and who remained				
DOI:	Pubmed ID:	DOI:	Pubmed ID:				
Pubmed Central ID:	Embase Id:	Pubmed Central ID:	Embase Id:				
NCT Number:	External Link:	NCT Number:	External Link:				
3580356		3580369					
Ref ID:	External ID:	Ref ID:	External ID:				
122							
Journal:		Journal:					
Pages Range: Volume	e: Issue:	Pages Range: Volu	me: Issue:				
Publication Date:		Publication Date:					
(10/20/2018 📋)		10/17/2018					
Language:		Language:					
eng		eng					
Affiliation:		Affiliation:					
Novartis Pharmaceuticals		Novartis Pharmaceuticals					
Conference Name: Confer	rence Location: Conference Date:	Conference Name: Conf	ference Location: Conference Date:				
Conflict of Interest:		Conflict of Interest:					
Corporate Author:		Corporate Author:					
Grant Information:		Grant Information:					
Drug or Device Name:	Drug or Device Manufacturer:	Drug or Device Name	Drug or Device Manufacturer				
Reset o	Keep Only This Record Merge t	o Fill Fields 🛄	ep Both Records Separately Canc				

#### 4. Merge to Fill Fields

While you can edit records by typing into each field (see above), you also have the option to auto-fill information from a de-duplicated record into the record you are keeping.

To 'fill fields' from the record on the right to the record on the left (i.e. from the duplicate record to the record that was kept in the nest), select "Merge to Fill Fields" at the bottom of the modal. This will result in:

- Any field that is empty on the left but filled on the right, being copied to the left.
- Any field that is filled on the left being left unchanged.

#### 5. Reset to Original Fields

Made an error and want to revert back to the original inputs? Click Reset.

### Implications for PRISMA

Based on the PRISMA 2020 Guidelines, Duplicate records are noted in the "Records Removed before Screening" section:



See our PRISMA page for more details on tracking studies through Search and Screening.

Permanent link: https://wiki.nested-knowledge.com/doku.php?id=wiki:autolit:search:duplicates&rev=1689604982

5/5

Last update: 2023/07/17 14:43